Novartis AG's Kisqali (ribociclib) is the first CDK4/6 inhibitor to show a significant overall survival advantage in HR+/HER2- advanced breast cancer, bolstering its position in the competitive market, where it has struggled to make substantial headway against Pfizer Inc.'s first-in-class Ibrance (palbociclib).
Novartis' Kisqali Scores Big Win In Competitive CDK4/6 Space
Data at ASCO showed a statistically significant overall survival advantage in pre- and perimenopausal women with advanced HR+, HER2- breast cancer, a first for the CDK4/6 class.
